Figure 1.

Characterization of patient derived HER2 mutant NSCLC xenograft models A. Comparative growth kinetics of DFCI 315 and DFCI 359. Each curve represents a separate mouse B. Representative H&E and HER2 immunohistochemistry stains. C. Expression of the HER2 755_757LREdelinsRP mutant in Ba/F3 cells results in IL-3 indepdent cell growth. D. HER2 755_757LREdelinsRP Ba/F3 cells are sensitive to HER2 kinase inhibitors. Cells were treated with different drugs at the indicated concentrations, and viable cells were measured after 72 hours of treatment and plotted relative to untreated controls.